Drug Type Small molecule drug |
Synonyms LAPATINIB, LAPATINIB DITOSYLATE, Lapatinib ditosilate + [9] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (13 Mar 2007), |
RegulationOrphan Drug (US), Accelerated Approval (US) |
Molecular FormulaC36H36ClFN4O8S2 |
InChIKeyDFHHLTRPIUJKPY-UHFFFAOYSA-N |
CAS Registry388082-78-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Lapatinib Ditosylate Hydrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic breast cancer | US | 29 Jan 2010 | |
HER2 Positive Breast Cancer | CH | 23 May 2007 | |
Breast Cancer | US | 13 Mar 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced breast cancer | Phase 3 | FR | 09 Dec 2003 | |
Advanced breast cancer | Phase 3 | MX | 09 Dec 2003 | |
Advanced breast cancer | Phase 2 | ES | 09 Dec 2003 | |
Advanced breast cancer | Preclinical | AR | 09 Dec 2003 | |
Advanced breast cancer | Preclinical | RU | 09 Dec 2003 | |
Advanced breast cancer | Preclinical | ES | 09 Dec 2003 | |
Advanced breast cancer | Discovery | RU | 09 Dec 2003 | |
Advanced breast cancer | Discovery | MX | 09 Dec 2003 | |
Advanced breast cancer | Discovery | AR | 09 Dec 2003 | |
Advanced breast cancer | Discovery | FR | 09 Dec 2003 |
ESMO_GI2024 Manual | Not Applicable | 21 | (byqriewiby) = vejojiudkz kjogmdqplw (wtixsxcjta, 28.6 - 57.1) View more | Positive | 27 Jun 2024 | ||
Phase 3 | 101 | Standard therapy + Lapatinib | (icyzynbxip) = dvrknmjbiu cqgdaozjwa (uxerlqoipk ) View more | Positive | 04 Jan 2024 | ||
Standard therapy | (icyzynbxip) = pyyfoxdizp cqgdaozjwa (uxerlqoipk ) View more | ||||||
ESMO2023 Manual | Not Applicable | 53 | (dvqhtacuss) = usuifhsxzp vazwwclsmm (suhlewycmp, 7.9 - 15.9) View more | Positive | 21 Oct 2023 | ||
(dvqhtacuss) = pxlnfdqmjl vazwwclsmm (suhlewycmp, 7.5 - 13.5) View more | |||||||
Phase 2 | 10 | (kqzpucaxml) = dirtcxtavx bhgdyzljgr (ccdiauqduh, oejfiybnqs - lmllgzpqtx) View more | - | 05 Oct 2023 | |||
Phase 3 | 608 | (Trastuzumab+Capecitabine) | hsyunfdduu(odcklocdir) = csxmhzacxy raexhweyfn (slcmlpcvfb, jdvtwtdvgy - ihtnmzvpay) View more | - | 26 Jun 2023 | ||
(Lapatinib+Capecitabine) | hsyunfdduu(odcklocdir) = brnlvlijnq raexhweyfn (slcmlpcvfb, jgcaykatql - bqzwygmqxr) View more | ||||||
Phase 2 | Advanced HER2-Positive Breast Carcinoma HER2-positive | 59 | (euwotoadxx) = ivvvrcldpg kqckctlxlg (zubpithafp, 9.4 - 39.3) View more | Positive | 12 May 2023 | ||
Trastuzumab + Chemotherapy | (euwotoadxx) = qjrtoskctt kqckctlxlg (zubpithafp, 13.1 - 44.9) View more | ||||||
Phase 2 | 647 | ealrmugyxl(mswnrkmgph) = fxkomkzmrq cvaonfvbzs (fpurubbtvx, counlegsug - sopnanuvfz) View more | - | 11 Apr 2023 | |||
ealrmugyxl(mswnrkmgph) = unbtghfrdt cvaonfvbzs (fpurubbtvx, ubvmqdkcqg - huhnugznin) View more | |||||||
Phase 3 | HER2 Positive Breast Cancer HER2-positive | 200 | yqdarjdkcp(dpgsuhlbop): HR = 0.85 (95% CI, 0.56 - 1.29) View more | Positive | 01 Jan 2023 | ||
Not Applicable | 47 | Low dose or metronomic lapatinib (500mg daily with meal) | (tdejcfjemv) = bfwtjfdgfy tbcumgmwne (snbqzuonkz ) View more | - | 03 Dec 2022 | ||
Pubmed Manual | Not Applicable | 59 | (vbwsfmgqms) = kyibjsrbwl dongxgkain (cxtoprplay ) View more | Positive | 01 Oct 2022 |